👨‍🎓 Final part of the ESMO Leaders Generation Programme ‘23-24. #ESMOLGP Thanks ESMO - Eur. Oncology 🙏 for the wonderful opportunity - such an inspiring journey & a privilege to share it with awesome colleagues throughout Europe 🌍. Go Group 1 😜! Looking forward to meeting again at #ESMO24.

BAD NEWS! -- Xevinapant +cis in HN Phase 3 negative at interim -- cis ineligible study closing down -- not great news for #hncsm #radonc NRG Oncology (h/t Yao Yu) C. Jillian Tsai, MD, PhD Sana Karam, MD, PhD Nancy Lee Henning Willers, MD emdgroup.com/en/news/xevina…

Great to see these papers out in tomasz baniak oncology today - four HNCIG consensus papers on (1) imaging and (2) pathological criteria for extranodal extension in HNC; and comprehensive assessments on disease endpoint definitions in (3) curative and (4) R/M HNSCC. Links below 👇

👇🏻 read this and consider signing. I did. Next step should be putting a real market value on the work peer-reviewers do (which btw is crucial)

Extremely happy to share my first-author paper out in Nature Communications dissecting how the epithelial-mesenchymal plasticity of cancer cells influences immunotherapy response! This is the core piece of my time at IDIBELL. 🧵below: nature.com/articles/s4146…

Puri Muñoz Marta López Victoria da Silva 🔻 Eva Gonzalez-Suarez lab CNIO Stop Cancer Manel Esteller Josep Carreras Leukaemia Research Institute (IJC) Marc Oliva IDIBELL Institut Català d'Oncologia Hospital Universitari Bellvitge | HUB Nature Communications Ministerio de Ciencia, Innovación y Universidades Agencia Estatal de Investigación GEM EMBO Many more insights in the main article and supplementary material, so have a closer look to all our findings! Hope you enjoy the reading, it’s been a long and challenging ride but we are one step closer to defeat #cancer! 👩🏻‍🔬 nature.com/articles/s4146…

And Brent is a great guy to work with too 🙌 - check out this opportunity 👇 Association of Cancer Physicians RCP London Trainees The Royal College of Radiologists National Oncology Trainees Research Collaborative BONUS

I’ld definitely work with him 🙂‍↕️🫰

Stop pembro after 2 years? In 43,359 pts that received up-front pembrolizumab for an advanced NSCLC, continuation beyond 2 years was not associated with better OS than a fixed 2-year treatment, HR = 0.97 [0.75–1.26] p = 0.95. Adrien Rousseau sciencedirect.com/science/articl…

Investigadors liderats per IDIBELL descobreixen biomarcadors que prediuen la resposta a la #immunoteràpia💊en el carcinoma de pell. Això podria permetre personalitzar el tractament d'aquest tumor. Publicat a #Nature Communications, llegeix més 👉 idibell.cat/2024/07/descob…

ATX preconditioning did not help… another study on gut Microbiome modulation to learn from. IMO we need to tackle patient selection and rethink drug development strategies in the field

*JUST LAUNCHED* First of its kind ESMO Resilience Task Force special workshop. 🌍 Are you an oncologist working in Europe? Interested in making a change for yourself & your institutions/countries? 🗳️ Come join us in Barcelona in 2025 - for more info: esmo.org/meeting-calend…

Join us tomorrow and Friday for the ESMO - Eur. Oncology Virtual Plenary on HNSCC👇🏻 Full program and how to access: esmo.org/meeting-calend…

📣 Starting today: Join us online for an in-depth presentation of the latest trial on head and neck cancer. International experts will analyze the results and answer audience questions. Open to all, don't miss out 👉 Connect at 18:30 CEST 🔗 ow.ly/Xbnf50SzlBb

📣 If you missed yesterday's session, the Experts Insight will be taking place today, with additional key opinion leaders for a more comprehensive approach and richer discussion. Connect today to the #ESMOVirtualPlenary at 13:00 CEST 🔗 ow.ly/pmba50Szmbt

The proportion of HPV-associated SNSCC is rising over time due to both a rise in the proportion of nasal cavity SNSCC and a decrease in HPV-independent maxillary sinus SNSCC, data suggest. ja.ma/3Scj52S

🎓ESMO Leaders Generation Programme Class of 2023-24: You guys are the BEST! It’s been such a great journey - really hope we get to continue working together going forwards! #ESMOLGP #ESMO24 Thanks Teresa Amaral, MD, PhD Andres Cervantes ESMO - Eur. Oncology for delivering a superb programme 🙏.